Cayman Enrofloxacin-D5; Size- 5 Mg

Rostafuroxin potently inhibits binding of endogenous ouabain to the Na⁺/K⁺ ATPase (IC₅₀ = 1.7 µM) through the Src-epidermal growth factor receptor (EGFR)-dependent signaling pathway. This blocks the ouabain-dependent increase in Na⁺/K⁺ ATPase activity. In cultured renal cells where the Na⁺/K⁺ ATPase is upregulated or has increased activity, rostafuroxin normalizes mRNA levels and Na⁺/K⁺ ATPase activity. At very low doses (1 and 10 µg/kg for 5-6 weeks) in Milan-hypertensive rats, it decreased the development of hypertension. In a Phase II clinical study, rostafuroxin did not reduce blood pressure in human patients at doses of 0.05-5.0 mg/d.

WARNING This product is not for human or veterinary use.